Tyrosine Kinase/Adaptateurs
Les inhibiteurs des tyrosines kinases et des adaptateurs sont des composés qui ciblent les tyrosines kinases et leurs protéines adaptatrices associées, jouant des rôles essentiels dans la signalisation cellulaire, la croissance et la différenciation. Ces inhibiteurs sont des outils essentiels dans la recherche sur le cancer, car de nombreuses tyrosines kinases sont impliquées dans les voies de signalisation qui favorisent la croissance tumorale et les métastases. En inhibant les tyrosines kinases, ces composés peuvent bloquer des cascades de signalisation cruciales, offrant ainsi des stratégies thérapeutiques potentielles pour divers cancers et autres maladies impliquant une signalisation cellulaire anormale. Chez CymitQuimica, nous offrons une gamme complète d'inhibiteurs de tyrosines kinases et d'adaptateurs de haute qualité pour soutenir vos recherches en oncologie, biologie moléculaire et développement de thérapies ciblées.
Sous-catégories appartenant à la catégorie "Tyrosine Kinase/Adaptateurs"
- ALK(112 produits)
- CSF-1R(42 produits)
- EGFR(572 produits)
- Récepteur Ephrin(23 produits)
- FLT(92 produits)
- Récepteur du facteur de croissance des fibroblastes (FGFR)(170 produits)
- SON(5 produits)
- Hck(3 produits)
- IGF-1R(86 produits)
- PDGFR(126 produits)
- PYK2(7 produits)
- Src(78 produits)
- Récepteur TAM(32 produits)
- Tie-2(20 produits)
- Récepteur Trk(59 produits)
- Tyrosine Kinases(27 produits)
- VEGFR(268 produits)
- c-Fms(108 produits)
- c-Kit(101 produits)
- c-Met/HGFR(128 produits)
- c-RET(51 produits)
Affichez 13 plus de sous-catégories
1375 produits trouvés pour "Tyrosine Kinase/Adaptateurs"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
EGFR-IN-22
CAS :<p>EGFR-IN-22: potent for EGFR (IC50: 4.91 nM) & L858R/T790M/C797S mutation (IC50: 0.54 nM).</p>Formule :C38H47BrFN10O2PCouleur et forme :SolidMasse moléculaire :805.72BLU-945
CAS :<p>BLU-945 is a reversible, potent, highly selective, and orally available epidermal growth factor receptor tyrosine kinase inhibitor (TKIs).Cost-effective and quality-assured.</p>Formule :C28H37FN6O3SDegré de pureté :99.11% - 99.16%Couleur et forme :SolidMasse moléculaire :556.7Duligotuzumab
CAS :<p>Duligotuzumab is a dual-targeting anti-EGFR/HER3 mAb that blocks signaling and induces ADCC for tumors with poor prognosis.</p>Degré de pureté :95% - 95%Couleur et forme :LiquidH1-7 (histone H1 phosphorylation site), PKA Substrate
CAS :<p>H1-7 (histone H1 phosphorylation site), a synthetic polypeptide serving as a PKA substrate, demonstrates utility in PKA substrate applications [1] [2].</p>Formule :C31H58N14O9Couleur et forme :SolidMasse moléculaire :770.88Etevritamab
CAS :<p>Etevritamab is a monoclonal antibody that targets CD3E/EGFR.</p>Couleur et forme :LiquidCofetuzumab
CAS :<p>Cofetuzumab (PF-06523435) is a antibody targeting protein tyrosine kinase 7 (PTK7), which can be used to synthesize ADC compounds like cofetuzumab pelidotin.</p>Degré de pureté :>95%Couleur et forme :Liquid[Pro3]-GIP (Mouse)
<p>GIP receptor blocker, 2.6μM IC50, hinders insulin release, regulates glucose in ob/ob mice, and enhances glucose tolerance.</p>Formule :C225H342N62O64SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :4971.62EGFR-IN-140
<p>EGFR-IN-140 (Compound 31) is an inhibitor of EGFR, effectively targeting both wild-type EGFR and the EGFRL858R/T790M/C797S mutant, with Ki values of 0.95 nM and 2.1 nM, respectively. Additionally, it inhibits EGFRdel19/T790M/C797S in Ba/F3 cells with an IC50 of 56.9 nM and demonstrates antitumor activity in mouse models.</p>Formule :C27H37FN8O2Couleur et forme :SolidMasse moléculaire :524.633PROTAC EGFR degrader 11
CAS :<p>PROTAC EGFR degrader 11 (Compound B71) is a PROTAC degrader targeting the epidermal growth factor receptor (EGFR), with a DC50 of less than 100 nM. It binds to CRBN-DDB1 with a Ki of 36 nM. This compound effectively degrades EGFR, focal adhesion kinase (FAK), and RSK1, and inhibits the proliferation of BaF3 wild-type and EGFR mutant cells, exhibiting an IC50 of less than 100 nM.</p>Formule :C49H64ClFN10O7SCouleur et forme :SolidMasse moléculaire :991.61cis-NVP-ADW742
CAS :<p>NVP-ADW742 is an IGF-1R inhibitor with IC50 of 0.17 μM, >16-fold more potent against IGF-1R than InsR; little activity to HER2, PDGFR, VEGFR-2, Bcr-Abl and c-Kit.</p>Formule :C28H31N5OCouleur et forme :SolidMasse moléculaire :453.59PKI (5-24),amide
CAS :<p>PKI (5-24),amide is a 20-residue peptide, a potent PKA inhibitor with a Ki of 2.3 nM, derived from a cAMP inhibitor protein.</p>Formule :C94H149N33O30Couleur et forme :SolidMasse moléculaire :2221.4ErbB-2-binding peptide
CAS :<p>ErbB-2-binding peptide (HER2-binding peptide), a tumor-targeting peptide, holds potential for cancer research applications [1].</p>Formule :C43H60N8O11Couleur et forme :SolidMasse moléculaire :864.98pYEEI
<p>pYEEI, a tetrapeptide containing phosphotyrosine, binds to the SrcSH2 domain with a dissociation constant (Kd) of 100 nM and an inhibitory concentration (IC50) of 6.5 μM. This compound plays a crucial role in cancer research.</p>Formule :C25H36N3O14PCouleur et forme :SolidMasse moléculaire :633.54SU 4981
CAS :<p>SU 4981 is an inhibitor of VEGFR and a modulator of tyrosine kinase activity.</p>Formule :C19H18N2O2Degré de pureté :95.4%Couleur et forme :SoildMasse moléculaire :306.36MS9427
CAS :<p>MS9427: PROTAC EGFR degrader, 7.1 nM (WT), 4.3 nM (L858R); targets mutant via UPS and autophagy; inhibits NSCLC cell growth; anticancer research.</p>Formule :C48H58ClFN8O12Couleur et forme :SolidMasse moléculaire :993.47Herceptide
CAS :<p>Herceptide (HER2-targeting peptide), a peptide that targets HER2, can be conjugated with the near-infrared fluorescent dye indocyanine green (ICG), facilitating the development of theranostic agents.</p>Formule :C76H110N22O23Couleur et forme :SolidMasse moléculaire :1699.82DDR Inhibitor 2
<p>DDR Inhibitor 2 (compound 5a) is a potent inhibitor of the discoidin domain receptor (DDR) with an IC50 value of 0.125 μM, and it is applicable in fibrotic disease research.</p>Formule :C21H23N7OCouleur et forme :SolidMasse moléculaire :389.19641EGFR T790M/L858R-IN-6
CAS :<p>EGFR T790M/L858R-IN-6 (compound 53), classified as a pyrimidine compound, serves as an effective inhibitor of EGFR T790M/L858R, demonstrating 90.88% inhibition of enzyme activity at a concentration of 0.05 μM [1].</p>Formule :C27H27N7O2Couleur et forme :SolidMasse moléculaire :481.55Fosgonimeton acetate
<p>Fosgonimeton acetate is an agonist of hepatocyte growth factor (HGF).</p>Formule :C29H49N4O10PDegré de pureté :98.01%Couleur et forme :SolidMasse moléculaire :644.69cFMS Receptor Inhibitor IV
CAS :<p>cFMS Receptor Inhibitor IV is an inhibitor of c-Fms tyrosine kinase.</p>Formule :C22H26N4O2Degré de pureté :99.70%Couleur et forme :SolidMasse moléculaire :378.47Simotinib hydrochloride
CAS :<p>Simotinib hydrochloride: selective oral EGFR inhibitor, IC50 19.9 nM, potent anticancer agent.</p>Formule :C25H27Cl2FN4O4Couleur et forme :SolidMasse moléculaire :537.41DP-C-4
<p>DP-C-4 is a Cereblon-based dual PROTAC for simultaneous degradation of EGFR and PARP[1].</p>Couleur et forme :LiquidPertuzumab
CAS :<p>Pertuzumab (anti-HER2) a humanized monoclonal antibody and the first in the class of agents called the HER2 dimerization inhibitors impairs the ability of HER2</p>Degré de pureté :98.00%Couleur et forme :LiquidMasse moléculaire :148 kDaEGFR/PI3Kα-IN-1
<p>EGFR/PI3Kα-IN-1 (compound 30k), a dual EGFR/PI3Kα inhibitor, exhibits potent activity with IC 50 values of 3.6 nM (EGFRL858R/T790M) and 30 nM (PI3Kα). It effectively inhibits tumor cell proliferation and demonstrates significant anticancer activity.</p>Formule :C50H49N11O5SCouleur et forme :SolidMasse moléculaire :916.06AZ14240475
<p>AZ14240475 is a potent, selective, brain-penetrant inhibitor of EGFREx20Ins mutants (EGFREx20Ins mutants) with a pIC50 of 7.6, playing a significant role in cancer research.</p>Formule :C23H15ClF2N6O2Couleur et forme :SolidMasse moléculaire :480.854Acrizanib
CAS :<p>Acrizanib (LHA510) is a VEGFR-2 inhibitor, with an IC50 of 17.4 nM for BaF3-VEGFR-2.</p>Formule :C20H18F3N7O2Degré de pureté :98.71% - 99.64%Couleur et forme :SolidMasse moléculaire :445.4WAY-270360
CAS :<p>WAY-270360 (N-[4-(1H-benzimidazol-2-yl)phenyl]-2,4-dimethoxybenzamide) is a sirtuin modulator and an epidermal growth factor receptor (EGFR) inhibitor.</p>Formule :C22H19N3O3Degré de pureté :98.05%Couleur et forme :SolidMasse moléculaire :373.4SJF 1528
CAS :<p>Potent EGFR & HER2 degrader; DC50 of 39.2 nM in OVCAR8, 736 nM in HeLa; has lapatinib, VHL ligand; inhibits HER2+ breast cancer (IC50=102 nM for SKBr3).</p>Formule :C55H57ClFN7O8SCouleur et forme :SolidMasse moléculaire :1030.61Vasonatrin Peptide (VNP)
CAS :<p>Vasonatrin peptide (VNP) is a chimera of atrial natriuretic peptide (ANP) and C-type natriuretic peptide (CNP) with potent venodilating and natriuretic activity</p>Formule :C123H198N36O36S3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :2865.37GW 583340
CAS :<p>GW 583340 is a potent and selective dual inhibitor of EGFR/ErbB2 tyrosine kinase with the advantage of oral dosability and antitumor effects.</p>Formule :C28H25ClFN5O3S2Degré de pureté :98.68%Couleur et forme :SoildMasse moléculaire :598.11PF-04217903 phenolsulfonate
CAS :<p>PF-04217903 phenolsulfonate is a potent ATP-competitive inhibitor of c-Met kinase (Ki of 4.8 nM for human c-Met).</p>Formule :C25H22N8O5SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :546.56Timigutuzumab
CAS :<p>Timigutuzumab (GEXMab73) is a humanized monoclonal antibody designed to target ErbB2, showing potential application in cancer research [1].</p>Couleur et forme :LiquidGefitinib N-oxide hydrochloride
<p>Gefitinib N-oxide hydrochloride is an N-oxide of EGFR inhibitor Gefitinib with IC50 of 2-37 nM.</p>Formule :C22H24ClFN4O41·5HClCouleur et forme :SolidMasse moléculaire :517.59Zenocutuzumab
CAS :<p>Zenocutuzumab (MCLA-128) is a humanized antibody targeting HER2, used for research on tumors driven by NRG1 gene rearrangement.</p>Degré de pureté :97%Couleur et forme :LiquidKemptide Phospho-Ser5
<p>Kemptide (Phospho-Ser5) is a phosphoreceptor peptide that is a specific substrate for camp-dependent protein kinase (PKA).</p>Formule :C32H62N13O12PDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :851.89GIP, human
CAS :<p>Insulinotropic hormone from K-cells, binds GIP receptors, boosts insulin, affects lipids, and has antiapoptotic properties.</p>Formule :C226H338N60O66SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :4983.6PROTAC EGFR degrader 3
CAS :<p>Potent PROTAC EGFR degrader 3; excellent against H1975/HCC827 cells; lysosome-involved mutant degradation.</p>Formule :C60H77N13O5SCouleur et forme :SolidMasse moléculaire :1092.4Eflapegrastim
CAS :<p>Eflapegrastim: humanized IgG4 antibody and G-CSF that boosts neutrophils and shortens neutropenia.</p>Couleur et forme :LiquidEGFR-IN-42
<p>EGFR-IN-42 (17b) is a potent EGFR inhibitor with nanomolar efficacy, merging tamoxifen/endoxifen and gefitinib, exhibiting enhanced anti-cancer action.</p>Formule :C49H53ClFN5O5Couleur et forme :SolidMasse moléculaire :846.43JBJ-09-063 TFA
<p>JBJ-09-063 TFA, an EGFR inhibitor selective for EGFR mutations, IC50s: 0.147-0.396 nM, blocks EGFR/Akt/ERK signaling, for EGFR-mutant lung cancer research.</p>Formule :C33H30F4N4O5SCouleur et forme :SolidMasse moléculaire :670.67evobrutinib
CAS :<p>Evobrutinib(M2951) , also known as M-2951 and MSC-2364447C, is a highly selective inhibitor of the Bruton's tyrosine kinase (BTK), which is important in the</p>Formule :C25H27N5O2Degré de pureté :98.03% - 99.58%Couleur et forme :SolidMasse moléculaire :429.51Anti-TrkB/NTRK2 Antibody
<p>Anti-TrkB/NTRK2 Antibody is a human-derived antibody produced in CHO cells, targeting TrkB. For the isotype control of Anti-TrkB/NTRK2 Antibody, refer to HumanIgG2kappa, Isotype Control.</p>Couleur et forme :Odour LiquidEGFR-TK-IN-5
<p>EGFR-TK-IN-5 (Compound NCE 2) is a thiazolyl pyrazoline derivative with significant inhibitory activity and stability against EGFR. It is applicable in tumor research.</p>Formule :C26H20ClFN4OSCouleur et forme :SolidMasse moléculaire :490.98IBI-334
<p>IBI-334 is a bispecific antibody targeting both B7-H3 and EGFR. It features an EGFR arm responsible for signal blocking, connected to a modified B7-H3 arm that ensures optimal affinity and binding. The antibody is afucosylated to enhance its antibody-dependent cellular cytotoxicity (ADCC) effects. IBI-334 is widely applicable in EGFR-driven solid tumors.</p>Couleur et forme :Odour LiquidInsulin efsitora alfa
CAS :<p>Insulin efsitora alfa(LY-3209590) is an IR agonist and a fusion protein that binds a novel single-chain insulin variant to the structural domain of human IgG Fc</p>Degré de pureté :98.3% (SDS-PAGE); 98.1% (SEC-HPLC) - 98.3% (SDS-PAGE); 98.1% (SEC-HPLC)Couleur et forme :LiquidEGFR-IN-162
<p>EGFR-IN-162 (compound 20) is an effective EGFR inhibitor that enhances both early and late apoptosis (EGFR) as well as necrosis (necrosis). It shows potential for use in breast cancer research.</p>Formule :C27H31N3O2Couleur et forme :SolidMasse moléculaire :429.24163MS9449
CAS :<p>MS9449 is a powerful EGFR PROTAC; Kd: 17 nM (WT), 10 nM (L858R); targets mutant EGFRs via UPS and autophagy; hinders NSCLC cell growth.</p>Formule :C60H76ClFN10O8SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :1151.82MS9427 TFA
<p>MS9427 TFA: PROTAC EGFR degrader, Kd 7.1 nM (WT), 4.3 nM (L858R), targets mutant EGFR, inhibits NSCLC cell growth, for cancer research.</p>Formule :C50H59ClF4N8O14Couleur et forme :SolidMasse moléculaire :1107.5PKI(5-24)
CAS :<p>High affinity PKA inhibitor (Ki = 2.3 nM).</p>Formule :C76H129N31O28Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :1925.057YH32367
<p>YH32367 (ABL105) is a bispecific antibody targeting HER2 and 4-1BB. It induces the secretion of IFN-γ, resulting in the death of tumor cells when co-cultured with hPBMC and HER2-expressing tumor cells. YH32367 demonstrates notable antitumor activity.</p>Couleur et forme :Odour Liquid
